Unfractionated heparin dose requirements targeting intermediate intensity antifactor Xa concentration during pregnancy

Pharmacotherapy

Volumn 30, Issue 4, 2010, Pages 369-374

  Clark, Nathan P ^a,b   Delate, Thomas ^b,c   Cleary, Steven J ^a   Witt, Daniel M ^b,c  

^a Clinical Pharmacy Anticoagulation Service   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Pharmacy Department   (United States)

Author keywords

Antifactor Xa monitoring; Intermediate dose heparin; Pregnancy; UFH; Unfractionated heparin; Venous thromboembolism; VTE

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG MONITORING; FEMALE; FRACTURE; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; OSTEOPENIA; PREGNANCY; PREGNANT WOMAN; RETROSPECTIVE STUDY; SUBCHORIONIC HEMATOMA; THROMBOEMBOLISM;

BLOOD COAGULATION FACTORS; BODY WEIGHT; CLINICAL PROTOCOLS; FEMALE; HEPARIN; HUMANS; PREGNANCY;

EID: 77950372167     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.4.369     Document Type: Article

References (20)

1. Chang JA, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance - United States, 1991-1999. MMWR Surveill Summ 2003;52:1-8.
2. Blanco-Molina A, Trujillo-Santos J, Criado J, et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE registry. Thromb Haemost 2007;97:186-190
3. Kujovich J. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004;191:412-424
4. Bates S, Greer I, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolisms, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:844-886
5. Ginsberg J, Hirsh J, Turner C, Levine M, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197-203.
6. Ginsberg J, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy: risks to fetus and mother. Arch intern Med 1989;149:2233-2236
7. Wesseling J, Van Driel D, Smrkovsky M, et al. Coumarins during pregnancy: long-term effects on growth and development in school age children. Early Hum Dev 2001;63:83-95.
8. Flessa H, Kapstrom A, Glueck H, Will J. Placental transport of heparin. Am J Obstet Gynecol 1965;93:570-573
9. Forestier F, Daffos F, Capella-Pavlosky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34:557-560
10. Copplestone J, Pavord S, Hunt B. Anticoagulation in pregnancy: a survey of current practice. Br J Haemotol 2004;124:123-125
11. Barbour L, Smith J, Mariar R. Heparin levels to guide thromboembolism prophylaxis during pregnancy. Am J Obstet Gynecol 1995;173:1869-1873
12. Brancazio L, Roperti K, Stierer R, Laifer S. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995;173:1240-1245
13. Dahlman T, Hellgren M, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol 1989;161:420-425
14. Chunilal S, Young E, Johnston M, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002;87:92-97
15. Raschke R, Guidry J, Foley M. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol 2000;96:804-806
16. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulant therapy. Chest 2005;127:1515-1522
17. Clark N, Delate T, Witt D, Parker S, McDuffie R. A descriptive evaluation of unfractionated heparin use during pregnancy. J Thromb Thrombolysis 2009;27:267-273
18. Zhang J, Yin W, Sun S, Alexander G. The impact of the Medicare part D prescription benefit on generic drug use. J Gen Intern Med 2008;23:1673-1678
19. Vesely R. Shifting the burden: reports show employers offloading costs to workers. Mod Healthcare 2008;38:8-9.
20. Fox N, Laughon S, Bender S, Saltzman D, Rebarber A. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 2008;112:884-889